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ABSTRACT:
Expression of breast cancer resistance protein (Bcrp) at the blood-
brain barrier (BBB) has been revealed recently. To investigate com-
prehensively the potential role of Bcrp at the murine BBB, a chem-
ically diverse set of model compounds (cimetidine, alfuzosin,
dipyridamole, and LY2228820) was evaluated using a multiexperi-
mental design. Bcrp1 stably transfected MDCKII cell monolayer
transport studies demonstrated that each compound had affinity
for Bcrp and that polarized transport by Bcrp was abolished com-
pletely by the Bcrp inhibitor chrysin. However, none of the com-
pounds differed in brain uptake between Bcrp wild-type and
knockout mice under either an in situ brain perfusion or a 24-h
subcutaneous osmotic minipump continuous infusion experimen-
tal paradigm. In addition, alfuzosin and dipyridamole were shown
to undergo transport by P-glycoprotein (P-gp) in an MDCKII-MDR1
cell monolayer model. Alfuzosin brain uptake was 4-fold higher in
mdr1a(/) mice than in mdr1a(/) mice in in situ and in vivo
studies, demonstrating for the first time that it undergoes P-gp-
mediated efflux at the BBB. In contrast, P-gp had no effect on
dipyridamole brain penetration in situ or in vivo. In fact, in situ BBB
permeability of these solutes appeared to be primarily dependent
on their lipophilicity in the absence of efflux transport, and in situ
brain uptake clearance correlated with the intrinsic transcellular
passive permeability from in vitro transport and cellular accumu-
lation studies. In summary, Bcrp mediates in vitro transport of
various compounds, but seems to play a minimal role at the BBB in
vivo.
The blood-brain barrier (BBB) is composed of brain capillary
endothelial cells, which are characterized by highly developed tight
junctions, a lack of fenestrations, and a paucity of pinocytic and
transcytotic activities. Expression of metabolic enzymes and efflux
transporters in these and associated glial cells provides additional
limiting factors at the BBB. Insufficient drug exposure at the phar-
macologic target within the brain, as a consequence of limited flux
from blood to brain, represents a major obstacle for effective treat-
ment of central nervous system (CNS) disorders (Begley, 2004;
Pardridge, 2005). It is widely accepted that P-glycoprotein (P-gp) is
expressed abundantly at the BBB and functions as an efflux pump that
extrudes toxic substances and therapeutic agents in the brain-to-blood
direction, representing a functional barrier to brain uptake (Schinkel,
1999). The potential role of other members of the ATP-binding
cassette (ABC) efflux transporter family, such as multidrug resis-
tance-associated proteins (Mrps) and breast cancer resistance protein
(Bcrp), at the BBB is less clear, although the proteins appear to be
expressed at the BBB in various species (Yousif et al., 2007).
Bcrp is a recently identified member of the ABC efflux transporter
family encoded by gene Abcg2 (Doyle et al., 1998). Bcrp is widely
expressed in the intestine, liver, mammary gland, and placenta. The
functional efficiency of Bcrp in these organs, such as intestinal se-
cretion, fetal penetration, and breast milk secretion of various com-
pounds (e.g., topotecan, nitrofurantoin, and cimetidine), has been
documented clearly (Jonker et al., 2000, 2005). In addition, Bcrp is
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expressed on the luminal side of brain capillary endothelial cells in
mice, rats, pigs, and humans, with localization similar to that of P-gp;
the mRNA expression level for Bcrp also is similar to that of P-gp
(Cooray et al., 2002; Cisternino et al., 2004; Aronica et al., 2005; Lee
et al., 2005; Tanaka et al., 2005).
Bcrp mediates the transport of a wide variety of substrates, from
sulfoconjugated organic anions to various organic cations. The exten-
sive overlap of Bcrp with P-gp in expression pattern (Tanaka et al.,
2005) and substrate specificity leads to the hypothesis that Bcrp, like
P-gp, might have an important role in the handling of substrate drugs,
with subsequent regulation of pharmacologic responses, in animals
and humans. However, studies to date have not clarified Bcrp function
at the BBB, which remains controversial. For example, the brain
penetration of imatinib mesylate was 2.5-fold higher in Bcrp-deficient
mice compared with that in wild-type animals, suggesting that Bcrp
contributes to the functional barrier to brain uptake of this compound
(Breedveld et al., 2005). In contrast, the initial rate of brain uptake of
imatinib mesylate did not differ between wild-type and Bcrp1(/)
mice during in situ brain perfusion, and GF120918, an inhibitor of
P-gp and Bcrp, did not alter brain uptake of imatinib in mdr1a/
1b(/) mice, leading to the conclusion that Bcrp was not involved
in imatinib brain uptake (Bihorel et al., 2007).
Exploring the role of Bcrp at the BBB may provide important
information on the design of efficient drug delivery to the CNS and
may add to the understanding of CNS toxicity for Bcrp substrates. In
the present study, four compounds with different physicochemical
properties, cimetidine, alfuzosin, dipyridamole, and LY2228820, were
selected as model substrates based on the in vitro screening in an
MDCKII-Bcrp cell monolayer transport assay to evaluate comprehen-
sively the role of Bcrp at the murine BBB (Fig. 1). Cimetidine, a
prototypical histamine H2 receptor antagonist, recently was demon-
strated to possess antitumor activity against a variety of cancers and
malignant brain glioma (Lefranc et al., 2006). Cimetidine is a hydro-
philic compound that has poor brain penetration (Hough et al., 1986)
and is actively secreted from rat mammary gland and placenta by Bcrp
(Jonker et al., 2005; Staud et al., 2006). Alfuzosin is a clinical
uroselective 1-adrenergic receptor antagonist with proven efficacy
and safety in the treatment of benign prostatic hyperplasia. Alfuzosin
is a structural analog of prazosin, which is a prototypical Bcrp
substrate (Staud et al., 2006). Dipyridamole is a platelet inhibitor used
for treatment of stroke. It was identified recently as a human BCRP
substrate (Zhang et al., 2005b). LY2228820 is a p38 mitogen-acti-
vated protein kinase inhibitor discovered by Eli Lilly and Company
(Indianapolis, IN) (Mader et al., 2008). In the present study, bidirec-
tional transport of these model compounds across the MDCKII-Bcrp
and MDCKII-MDR1 cell monolayers was evaluated. The initial brain
uptake clearance (Clup) was determined using in situ brain perfusion
with Bcrp-competent (wild type) and Bcrp-deficient [Abcg2(/)],
P-gp-competent [mdr1a(/)], and P-gp-deficient [mdr1a(/)]
mouse models. In addition, the P-gp and Bcrp inhibitor GF120918
was coperfused with test compounds in the brain perfusion paradigm
to generate a chemical knockout model. Finally, in vivo brain pene-
tration of substrates was measured at 24 h during continuous subcu-
taneous infusion with an osmotic minipump.
Materials and Methods
Animals. Adult male mdr1a(/) and their natural mutant mdr1a(/)
CF-1 mice (30–40 g) were obtained from Charles River Laboratories, Inc.
(Wilmington, MA). Male Abcg2(/) and Abcg2(/) mice (25–35 g) were
provided by Deltagen, Inc. (San Mateo, CA) and a gift from Eli Lilly and
Company. Ungenotyped male C57BL/6 mice from Charles River Laboratories,
Inc. were used as control wild-type mice, e.g., assumed to be Abcg2(/) or
Abcg2(/), because spontaneously recessive mutants are not reported to
occur. Details regarding the background, generation, and breeding of these
mice have been described elsewhere (Zamek-Gliszczynski et al., 2006). All
mice were maintained on a 12-h light/dark cycle with access to water and food
ad libitum. All experimental procedures were performed under full anesthesia
induced with ketamine/xylazine (100/10 mg/kg i.p.). All procedures were
approved by the Institutional Animal Care and Use Committee at the Univer-
sity of North Carolina at Chapel Hill and were conducted in accordance with
Guide for the Care and Use of Laboratory Animals (National Institutes of
Health publication 85-23, revised in 1985).
Materials. Cimetidine and dipyridamole were purchased from Sigma-Al-
drich (St. Louis, MO). Alfuzosin was obtained from Toronto Research Chem-
icals Inc (North York, ON, Canada). LY2228820 and [14C]LY2228820 were
kind gifts from Eli Lilly and Company. GF120918 was a kind gift from
GlaxoSmithKline (Research Triangle Park, NC). [3H]Cimetidine (25.0 Ci/
mmol) and [14C]diazepam (56.0 mCi/mmol) were purchased from GE Health-
care (Little Chalfont, Buckinghamshire, UK). [14C]Inulin (2.1 mCi/g) was
purchased from American Radiolabeled Chemicals (St. Louis, MO). [3H]Inulin
(180.0 mCi/g) and [3H]colchicine (80.4 Ci/mmol) were purchased from
PerkinElmer Life and Analytical Sciences (Waltham, MA). LSN335984 is a
dichloro homolog of the difluoro-containing zosuquidar (LY335979), which
was developed as a third-generation, specific inhibitor of P-gp (Pfister et al.,
1995; Yasuno et al., 2008). All of the other chemicals were commercially
available and of reagent grade.
Cell Culture. MDCKII cells stably expressing either murine wild-type
Abcg2 (Bcrp1) or human wild-type ABCB1 (P-gp) were obtained from the
Netherlands Cancer Institute under a Materials Transfer Agreement. MDCK
cells were maintained at 37°C in humidified 5% CO2/95% air using Eagle’s
minimal essential culture medium supplemented with 10% (v/v) fetal bovine
serum, penicillin, and streptomycin. A 1:10 split was done twice per week, and
cells at passages 7 to 10 (Bcrp) or 20 to 30 (P-gp) were plated at 50,000
cells/cm2 in 12-well Transwell filter inserts (1.13 cm2 surface area). Medium
was changed on days 3 and 5, and the cell monolayers were used on day 6.
Bidirectional Flux Experiments in Vitro. Cells were rinsed twice with
Dulbecco’s phosphate-buffered saline (PBS) containing 10 mM Hepes, pH 7.4.
Some cells were pretreated twice for 15 min each with PBS containing either
2.5 M LSN335984 to potently and selectively inhibit P-gp and not Bcrp, or
20 M chrysin to specifically inhibit Bcrp and not P-gp (Zhang et al., 2005a).
Transport was measured in both directions across uninhibited and inhibited cell
monolayers using a substrate concentration of 5 M diluted from a 10-mM
DMSO stock solution (final DMSO concentration of 0.05%) and a single
60-min time interval (screening mode). The upper chamber (A) contained 0.5
ml of PBS and the lower chamber (B) contained 1.0 ml of PBS without and
with inhibitor. The system was mixed using a Clay-Adams Nutator and kept at
37°C in room atmosphere. Solute concentration was determined for the donor
and receiver solutions, and mass balance was achieved by extracting the cells
with methanol. The apparent permeability coefficients (Papp) were estimated as
the slope of the mass transported per 60 min relative to the total recovered
mass according to Ho et al. (2000). B-A/A-B Papp ratios were calculated for







































FIG. 1. Chemical structures of cimetidine (A), alfuzosin (B), dipyridamole (C), and
LY2228820 (D).
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[14C]mannitol in the absence and presence of solute and DMSO. The contri-
bution of permeability at the aqueous boundary layer (PABL) was measured
using the Papp of [
14C]testosterone (Ho et al., 2000). Positive controls run
periodically included amprenavir for P-gp and prazosin for Bcrp with triam-
terene as control for a nonsubstrate. Experiments were done in duplicate at
least twice. All test solutes were quantified by reverse-phase high-performance
liquid chromatography with detection by tandem mass spectrometry (HPLC-
MS/MS) as detailed below.
Mouse Brain Capillary Depletion. Brain capillaries from wild-type and
Abcg2(/) C57BL/6 mice were isolated using the method of Dallaire et al.
(1991) with some modifications. In brief, 8 to 10 animals/group were eutha-
nized by CO2 inhalation, and the brains were quickly removed and placed in
ice-cold capillary buffer consisting of 147 mM NaCl, 4 mM KCl, 3 mM CaCl2,
1.2 mM MgCl2, 5 mM glucose, and 15 mM HEPES, pH 7.4. The tissue was
kept on ice at 4°C throughout the procedure. Large surface blood vessels were
removed, and the brains from each animal group were pooled together. The
tissue was then minced with a razor blade and added to a Potter-Elvehjem
homogenizer (clearance 0.15–0.23 mm) along with 4 volumes of capillary
buffer. Brains were homogenized with 10 strokes at approximately 500 revo-
lutions/min. The homogenate was centrifuged in a fixed-angle rotor at 3500g
for 10 min, and the supernatant was discarded. The pellet was resuspended
with 4 volumes of 20% Ficoll T-400. The tissue was then homogenized with
a loose-fitting Teflon pestle (0.23 mm) with 20 strokes. The suspension was
centrifuged in a fixed-angle rotor at 25,000g for 10 min at 4°C. The myelin
layer floating at the top was carefully removed along with the remaining
supernatant. The pellet was resuspended in 15 ml of 15% dextran T-500
(Sigma-Aldrich) and layered onto 5 ml of 20% dextran T-500. The gradient
was centrifuged in a SW-28 swinging bucket rotor (Beckman Coulter, Fuller-
ton, CA) at 25,000g for 10 min at 4°C. The supernatant was aspirated, and the
pellet was resuspended in capillary buffer plus 1% bovine serum albumin
(BSA). This was applied to a prewetted 2.5  4 cm, 0.5-mm diameter glass
bead column (Sartorius AG, Goettingen, Germany). The capillaries were
washed with 75 ml of capillary buffer-BSA. The beads were transferred into a
200-ml beaker, and the capillaries were detached from the beads by gently
swirling in 50 ml of buffer-BSA. The isolated capillaries were decanted and
centrifuged at 300g for 10 min. The supernatant was discarded, and the pellet
was rinsed with 50 ml of capillary buffer and centrifuged again; this process
was repeated one additional time. The final pellet was resuspended in capillary
buffer and stored at 70°C until further use. The purity of the capillary
fraction was determined by measuring -glutamyl transpeptidase activity ac-
cording to Orlowski and Meister (1965). The activity in isolated capillaries was
compared with whole brain homogenate activity levels. The enzyme activities
for the capillary fractions from the three groups of animals were in excess of
20-fold greater than those for the whole brain homogenates and therefore were
judged to be acceptable for Western blot analysis.
Western Blot Analysis. Isolated capillary and whole brain homogenate
samples were lysed for 30 min at 4°C in a buffer containing 150 mM NaCl, 100
mM Tris-HCl, pH 7.5, 1% Triton X-100, and protease inhibitors. Protein
concentrations were determined using a BCA assay kit (Sigma-Aldrich). The
lysates were electrophoresed on a 4 to 12% SDS-polyacrylamide gel and then
transferred to polyvinylidene difluoride membranes (Invitrogen, Carlsbad,
CA). The membrane was blocked in Dulbecco’s phosphate-buffered saline
containing 0.1% Tween 20 (PBST) and 5% nonfat dry milk (Bio-Rad, Her-
cules, CA) for 2 h at room temperature. The membrane was briefly washed
with PBST and then incubated overnight at 4°C with a 1:25 dilution of
anti-mouse Bcrp in PBST (BXP-53 clone; Kamiya Biomedical Company,
Seattle, WA). The membrane was then washed three times for 10 min each and
incubated with an horseradish peroxidase-conjugated goat anti-rat secondary
antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA),
diluted 1:10,000 in PBST. Proteins were detected using the ECL system (GE
Healthcare).
In Situ Mouse Brain Perfusion. The details of the in situ mouse brain
perfusion have been described elsewhere (Dagenais et al., 2000). In brief, mice
were anesthetized with ketamine/xylazine (100/10 mg/kg i.p.). The right com-
mon carotid artery was cannulated with polyethylene tubing (0.30-mm inner
diameter  0.70-mm outer diameter; Biotrol Diagnostic, Chennevières-les-
Louvres, France) after ligation of the external carotid artery. The cardiac
ventricles were severed immediately before perfusion at 2.5 ml/min for 60 s via
a syringe pump (Harvard Apparatus Inc., Holliston, MA). The perfusion buffer
(Krebs-bicarbonate buffer, with 9 mM D-glucose, pH 7.4) was oxygenated with
95% O2 and 5% CO2 and maintained at 37°C. [
14C]Diazepam and [3H]- or
[14C]inulin were used as blood flow rate and vascular space markers, respec-
tively. The test compound, [3H]cimetidine (1.6 Ci/ml), [14C]LY2228820 (0.1
Ci/ml), alfuzosin (2 M), or dipyridamole (1, 2, and 5 M), was added to the
perfusate to achieve appropriate concentrations. GF120918 and dipyridamole
were dissolved in DMSO. The final concentration of DMSO in the perfusate
was less than 2%. GF120918 (2 M) was coperfused with alfuzosin and
dipyridamole to inhibit P-gp and Bcrp. The experiment was terminated by
decapitation. The brain was removed carefully from the skull and cleaned of
meninges and choroid plexus, the cerebellum was excised, and the right brain
hemisphere was collected. Aliquots of perfusate were collected from the
catheter and weighed for determination of perfusate concentration.
All nonradioactive samples were analyzed by HPLC-MS/MS. Radioactive
brain samples were digested in 0.7 ml of Solvable (PerkinElmer Life and
Analytical Sciences, Waltham, MA) at 50°C overnight. Five milliliters of
UltimaGold scintillation cocktail (PerkinElmer Life and Analytical Sciences,
Wellesley, MA) was added and vortex-mixed. Total radioactivity (3H and/or
14C) was determined in a Packard Tri-Carb TR 1900 liquid scintillation
analyzer (PerkinElmer Life and Analytical Sciences). Parameters related to the
in situ mice brain perfusion, i.e., the cerebral vascular volume (milliliters per




The initial brain uptake clearance (Clup, milliliters per minute per 100 g of




where the amount of substrate in brain, Xbrain, was corrected for residual blood
contamination (Dagenais et al., 2000).
Osmotic Minipump Studies. Mdr1a(/), mdr1a(/), wild-type, and
Abcg2(/) mice (n  3) were anesthetized with ketamine/xylazine (100/10
mg/kg i.p.). An Alzet 2001D osmotic minipump (Alza, Palo Alto, CA) was
selected to release the drug continuously over 24 h to achieve a steady-state
condition at a flow rate of 8 l/h. The concentration of the dosing solution was
adjusted to the average animal body weight and mean pump rate to deliver an
appropriate dose. Cimetidine, alfuzosin, and dipyridamole were dissolved in
50% DMSO and loaded into the minipumps. Cimetidine (200 g/pump,
approximately 6.4 mg/kg/day) was implanted subcutaneously in the back of
wild-type and Abcg2(/) mice. Alfuzosin (200 g/pump, approximately 6.4
mg/kg/day) and two doses of dipyridamole (40 and 400 g/pump, approxi-
mately 1.28 and 12.8 mg/kg/day, respectively, with the higher dose dissolved
in 80% DMSO to ensure adequate solubility) were implanted subcutaneously
in mdr1a(/), mdr1a(/), wild-type, and Abcg2(/) mice. The exper-
iments were terminated at 24 h by decapitation. The brain was removed
carefully from the skull and weighed. Trunk blood was collected in heparinized
1.5-ml microcentrifuge tubes. Plasma was harvested after centrifugation at
3000 rpm for 5 min. The plasma and brain samples were stored at 20°C until
analysis by HPLC-MS/MS. To ensure reliable drug release during the dosing
period, the minipump was removed from the body and the residual volume was
measured.
HPLC-MS/MS Assay. Two volumes of distilled water were added to brain
samples and homogenized with brief probe sonication. Plasma, brain homog-
enate, and perfusate samples were analyzed by HPLC-MS/MS (API 4000 triple
quadrupole with TurboIonSpray interface; Applied Biosystems/MDS Sciex,
Concord, ON, Canada). A 25-l aliquot of brain hemisphere homogenate or
plasma was transferred to an HPLC vial, and protein was precipitated with 100
l of methanol containing internal standard (10 ng/ml loperamide), followed
by a 25-l aliquot of DMSO. The sample was vortex-mixed and centrifuged.
Three microliters of sample solutions were injected via an autosampler (Leap
Technologies, Carrboro, NC). Cimetidine, alfuzosin, dipyridamole, and the
internal standard, loperamide, were eluted from an Aquasil C18 column (2.1 
50 mm, dp  5 m; Thermo Fisher Scientific, Waltham, MA) using a mobile
phase gradient [A, 0.1% formic acid in water; B, 0.1% formic acid in meth-
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anol; 0- to 0.70-min hold at 0% B, 0.70- to 3.12-min linear gradient to 90% B,
3.12- to 4.10-min hold at 90% B, 4.10- to 4.20-min linear gradient to 0% B,
4.20- to 4.90-min hold at 0% B; Shimadzu (Kyoto, Japan) solventdelivery
system; flow rate  0.75 ml/min; 0.8–4 min directed to mass spectrometer]
and were detected in positive ion mode using multiple reaction monitoring:
cimetidine, 253.1 3 117.0 m/z; alfuzosin, 390.2 3 235.2 m/z; and dipyrid-
amole, 505.5 3 429.3 m/z. All analytes were quantified with standard curves
(0.05–5000 ng/ml) prepared in the appropriate matrix. The lower limit of
detection was 0.1 ng/ml for all analytes; inter- and intraday relative standard
deviations were 15%.
Statistical Analysis. Data are reported as mean  S.D. for three mice per
condition (n  3). A two-tailed Student’s t test or one-way or two-way analysis
of variance (ANOVA), where appropriate, was used to determine the statistical
significance of differences among two or more groups. The level of signifi-
cance was corrected for multiple comparisons (e.g., Bonferroni test) or ad-
justed for unequal variance when necessary. In all cases, p  0.05 was
considered to be statistically significant.
Results
In Vitro Transport. The B-A/A-B Papp ratios for each of the four
compounds tested ranged from 16 to 37, suggesting that each com-
pound underwent active efflux across MDCKII-Bcrp cell monolayers.
The positive control prazosin had a ratio of 27, which compared
favorably to historical data (mean  S.D.) of 22  7 (n  17) (G. A.
Sawada and T. J. Raub, unpublished data). In addition, the B-A/A-B
Papp ratios were decreased substantially (to 1.1–2.0) in the presence of
the Bcrp inhibitor chrysin (Table 1). Prazosin efflux by MDCKII-Bcrp
was not inhibited by the specific P-gp inhibitor LSN335984 (data not
shown). Cellular substrate concentrations at equilibrium, estimated by
methanol wash, of alfuzosin, dipyridamole, and [14C]LY2228820,
were decreased 4-fold in Bcrp-expressing cells because of active
efflux, whereas cellular cimetidine concentrations were very low and
unaffected by Bcrp. Alfuzosin and dipyridamole also were identified
as P-gp substrates when substrate flux was evaluated in the MDCK-
MDR1 cell monolayer model, with P-gp-mediated transport inhibited
by the P-gp inhibitor LSN335984 (Fig. 2). In these cases, cellular
concentrations at equilibrium were decreased 4- to 6-fold in the presence
of P-gp-mediated efflux. Amprenavir efflux by MDCKII-MDR1 was not
inhibited by the Bcrp inhibitor chrysin (data not shown).
Bcrp Expression at the BBB. The expression of Bcrp in whole
brain homogenate and isolated brain capillaries is shown in Fig. 3.
There was no Bcrp detected in any of the whole-brain homogenate
samples from the three mouse strains, whereas a protein band of 70
kDa was present in isolated brain capillaries. This suggested that Bcrp
is expressed primarily at the BBB in wild-type and Abcg2(/) mice,
and, as expected, Bcrp is completely absent in Abcg2(/) mouse
brain capillaries.
In Situ Brain Perfusion. [14C]Inulin was used as a brain capillary
space marker to assess BBB physical integrity. BBB integrity was not
changed by knockout of the mdr1a or Abcg2 gene or by coperfusion
with 2 M GF120918. In addition, the brain capillary volumes in
wild-type and Abcg2(/) mice were comparable to those in CF-1
mice (Vvasc  1.69  0.10 ml/100 g). The cerebral blood flow rates
in wild-type and Abcg2(/) mice also were similar to that in CF-1
mice, measured using [14C]diazepam as the marker (250  41 ml/
min/100 g).
The values of the initial brain uptake clearance of [3H]cimetidine
and [14C]LY2228820 in all four mouse strains, i.e., wild-type and
Abcg2(/) C57BL/6 and mdr1a(/) and mdr1a(/) CF-1 mice,
are presented in Table 2. Cimetidine does not cross the BBB to an
appreciable extent. Cimetidine Clup increased by 33% but did not
reach statistical difference (1.1  0.4 versus 0.8  0.3 ml/min/100 g,
p  0.05) when coperfused with 2 M GF120918 in wild-type mice.






LY2228820 (all at 5 M) across MDCKII-Bcrp cell monolayers in the absence () or
presence () of Bcrp inhibitor chrysin (20 M)
The intrinsic transmonolayer permeability coefficient (Pcell) was calculated using a measured PABL  80  10
6 cm/s (Ho et al., 2000). Mass recoveries were 92 to 112%.
Compound Name Inhibitor
Papp  S.D.
B-A/A-B Papp ratio Pcell
A-B B-A
 106 cm/s  106 cm/s
Cimetidine  1.4  0.2 23  2 16
 1.8  0.2 3.6  0.3 2.0 0.2
Alfuzosin  1.9  0.002 60  1 31
 25  1 30  2 1.2 1.6
Dipyridamole  2.6  10.0 90  0.3 34
 48  1 70  3 1.5 3.4
LY2228820  3.9  0.2 143  1 37
 44  3 50  8 1.1 44
PABL, permeability coefficient for the aqueous boundary layer.



















FIG. 2. Apparent permeability (Papp, 10
6 centimeters per second) of alfuzosin
(AL) and dipyridamole (DP) across the MDCKII-MDR1 cell monolayer in A-B (f)
and B-A () directions in the absence (AL and DP) or presence (ALI and DPI)
of the P-gp inhibitor LSN335984 (2.5 M).
1       2         3      4        5    6
H      C        H     C       H    C
71 kD
Abcg2(+/-)  Abcg2(+/+)  Abcg2(-/-)
FIG. 3. BBB Bcrp expression in whole brain homogenates (H) and isolated capil-
laries (C). An 70-kDa band was present in the enriched capillary fraction from
both wild-type (lane 2) and Abcg2(/) (lane 4) mice, but expression was not
detected in Abcg2(/) mouse capillaries (lane 6). There was no Bcrp detected in
any of the whole brain homogenate samples from wild-type (lane 1), Abcg2(/)
(lane 3), or Abcg2(/) (lane 5) mice.
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brain uptake in mdr1a(/) mice was close to the functional perfus-
ate flow rate and was 2.3-fold higher than that in mdr1a(/) mice
(p  0.05). [14C]LY2228820 was also perfused in Abcg2(/) mice
and the Clup was 120  9 ml/min/100 g of brain, which did not differ
significantly from that in wild-type and Abcg2(/) mice (136  3
and 131  26 ml/min/100 g, one-way ANOVA, p  0.05).
Alfuzosin brain uptake was moderate in all mouse strains. The
inhibitory effect of GF120918 on P-gp- and/or Bcrp-mediated alfuzo-
sin efflux is illustrated in Fig. 4. Figure 4A shows that alfuzosin brain
uptake is comparable in wild-type and Abcg2(/) mice in the
absence of GF120918 (p  0.05). Coperfusion with GF120918 sig-
nificantly increased alfuzosin brain uptake in both wild-type and
Abcg2(/) mice (p  0.05, inhibitory effect) but to a greater extent
in Abcg2(/) mice (p  0.05, strain difference). The increased
alfuzosin brain uptake can be ascribed to P-gp inhibition in the BBB
by GF120918. Figure 4B demonstrates that alfuzosin brain uptake
increased 3.7-fold in mdr1a(/) mice compared with that in
mdr1a(/) mice (p  0.05). In a consistent manner, alfuzosin brain
uptake increased approximately 4.4-fold with GF120918 coperfusion
in mdr1a(/) mice (p  0.05). GF120918 had no effect on alfuzo-
sin brain uptake in mdr1a(/) mice.
Three concentrations (1, 2, and 5 M) of dipyridamole were
perfused in wild-type and Abcg2(/) mice, respectively (Fig. 5).
Two-way ANOVA analysis indicated that there were no statistical
differences between these two mouse strains at any of the concen-
trations tested or among concentrations in any mouse strain ( p 
0.05).
Figure 6 depicts dipyridamole brain uptake when perfused at 2 M
in the absence or presence of 2 M GF120918 in all four mouse
strains. Dipyridamole brain uptake did not differ between wild-type
and Abcg2(/) mice or between mdr1a(/) and mdr1a(/)
mice. Figure 6A illustrates that dipyridamole brain uptake was in-
creased by 2.2-fold in the presence of 2 M GF120918 coperfusion in
both wild-type and Abcg2(/) mice, respectively (two-way
ANOVA, p  0.05). Coperfusion of GF120918 increased dipyridam-
ole brain uptake by 1.4-fold in mdr1a(/) and mdr1a(/) mice,
although the differences were not statistically significant (p  0.05;
two-way ANOVA) (Fig. 6B).
Osmotic Minipump Studies. The vehicle, DMSO, up to 50% in
water has been reported to be compatible with the minipump
(www.alzet.com). The osmotic minipumps provided reliable deliv-
ery of cimetidine, alfuzosin, and dipyridamole (at a dose of 1.28
mg/kg/day). However, with the dipyridamole administration rate of
12.8 mg/kg/day, precipitation was visible around the exit hole of
the device at the end of the experiment, and the plasma and brain
concentrations were highly variable; thus, these data were ex-
cluded for comparison. Cimetidine brain/plasma concentration ra-
tios were 0.024  0.005 and 0.020  0.017 in wild-type and
Abcg2(/) mice, respectively (Student’s t test, p  0.05). The
brain/plasma concentration ratios of alfuzosin and dipyridamole
(1.28 mg/kg/day) are shown in Fig. 7. Alfuzosin brain penetration
was significantly higher (4.1-fold) in mdr1a(/) mice than in
mdr1a(/) mice (Student’s t test, p  0.05). Alfuzosin and
dipyridamole brain penetration was 3.5-fold higher in
Abcg2(/) mice than in wild-type mice, although these differ-
ences did not achieve statistical significance. In addition, dipyrid-
amole brain penetration was comparable between mdr1a(/) and
mdr1a(/) mice (Student’s t test, p  0.05).
TABLE 2
Initial brain Clup for 	
3H
cimetidine and 	14C
LY2228820 in wild-type and Abcg2(/) C57BL/6 mice and mdr1a(/) and mdr1a(/) CF-1 mice
Data are presented as mean  S.D. (n  3). Two-tailed Student’s t tests were used to determine the statistical significance of the Bcrp effect between wild-type and Abcg2(/) mice and
the P-gp effect between mdr1a(/) and mdr1a(/) mice.
Clup
Wild-Type Bcrp(/) mdr1a(/) mdr1a(/)
ml/min/100 g
Cimetidine 0.8  0.3 0.5  0.1 0.7  0.2 1.1  0.4
LY2228820 136  33 131  26 104  8 239  24*
* Statistical difference (p  0.05) between mdr1a(/) and mdr1a(/) mice for 	14C



























































FIG. 4. Initial brain Clup (milliliters per minute per 100 g of brain) of alfuzosin in
the absence (f) and presence () of coperfusion with P-gp and the Bcrp inhibitor
GF120918 in wild-type and Abcg2(/) mice (A) and in mdr1a(/) and
mdr1a(/) mice (B). Two-way ANOVA analysis was used to determine the
statistical significance of the GF120918 inhibitory effect and Bcrp effect [wild-type
versus Abcg2(/)] or P-gp effect [mdr1a(/) versus mdr1a(/)]. , statistical
difference (p  0.05) with GF120918 inhibition; †, statistical difference (p  0.05)






























FIG. 5. Initial brain Clup (milliliters per minute per 100 g of brain) for dipyridamole
at different concentrations (1, 2, and 5 M) in wild-type and Abcg2(/) mice.
Two-way ANOVA was used to determine the statistical significance of concentra-
tion dependence and the Bcrp effect (p  0.05).
1255Bcrp PLAYS A MINOR ROLE AT MURINE BBB
BBB Penetration, in Vitro Prediction, and Physicochemical
Relationship. It has been demonstrated that BBB permeability is
primarily dependent on the lipophilicity for compounds that undergo
solely passive diffusion at the BBB (Takasato et al., 1984). Figure 8A
demonstrates that in the absence of P-gp, the Clup values for cimeti-
dine, alfuzosin, dipyridamole, and LY2228820 in mdr1a(/) mice
were correlated (R2  0.956) with clogD7.4, the calculated logarithm
of the octanol-water partition coefficient at pH 7.4. The values of
clogD7.4 were 0.12, 0.56, 3, and 6.3 for cimetidine, alfuzosin, dipy-
ridamole, and LY2228820, respectively, and were obtained using
Marvin and calculator plug-in freeware (ChemAxon Kft, Budapest,
Hungary; www.chemaxon.com). In addition, the in situ brain perme-
ability has been found to be correlated with in vitro apparent perme-
ability (Summerfield et al., 2007). There is a curvilinear relationship
between the Clup in Abcg2(/) mice [Clup(/)] and the Papp, AB
or Papp, BA in the MDCKII-Bcrp cell line when Bcrp was completely
inhibited by chrysin (Fig. 8B). This curvilinearity was attributed to the
aqueous boundary layer affecting the more lipophilic compounds in
monolayer transport studies (Ho et al., 2000). To demonstrate this
behavior, the Papp for each compound was corrected for the aqueous
boundary layer to give the intrinsic transmonolayer permeability
coefficient (Pcell) (Table 1). Consequently, the linear correlation be-
tween Clup(/) and Pcell was markedly improved (R
2  0.997) (Fig.
8C). In addition, Clup(/) was correlated with the in vitro cellular
accumulation of compound (R2  0.952) (Fig. 8D). These correlation
analyses suggest that the cell line model may serve as a high-through-
put in vitro system to predict passive permeability and contribute to
improved compound selection in CNS drug discovery and develop-
ment.
Discussion
Bcrp mediates intestinal and biliary secretion and substrate extru-
sion at mammary epithelia and in the placenta, and it plays an
important pharmacologic and toxicologic role in the absorption and
disposition of xenobiotics and xenotoxins (Jonker et al., 2000, 2005).
However, the extent to which Bcrp might influence brain distribution
of known Bcrp substrates has been unclear. In the current study we
investigated the functional efficiency of Bcrp in vitro, in situ, and in
vivo using four model compounds: cimetidine, alfuzosin, dipyridam-
ole, and LY2228820.
Asymmetric transport of cimetidine was mediated by Bcrp in
transfected MDCK cell lines (Table 1), as evidenced by a B-A/A-B
Papp ratio of 16. Under similar experimental conditions, a B-A/A-B
Papp ratio of 9 has been reported (Pavek et al., 2005). Cimetidine
was transported actively by Bcrp in an MDCKII-Bcrp1 cell line as
well as in rat and mouse liver and rat placenta (Merino et al., 2005;
Staud et al., 2006). However, in the current study Abcg2 gene knock-
out did not change the initial rate of brain uptake or steady-state brain
distribution using in situ brain perfusion and in vivo brain penetration
paradigms. In addition, cimetidine brain uptake was independent of
P-gp and Bcrp inhibition by GF120918. Furthermore, cimetidine brain
penetration was minimal during a 24-h continuous subcutaneous
infusion, and steady-state brain/plasma concentration ratios in wild-
type and Abcg2(/) mice were similar to a previously published
value of 0.017 after intraperitoneal injection of cimetidine (100 mg/
kg) in rats (Hough et al., 1986). The present results indicate that Bcrp
does not pose a substantial barrier for cimetidine brain uptake and that
the poor brain penetration of cimetidine is primarily due to low
passive permeability.
This study constitutes the first investigation of alfuzosin interaction
with ABC efflux transporters. Alfuzosin Clup and the brain/plasma
concentration ratio in mdr1a(/) mice were 4.4- and 4.1-fold higher
than those in mdr1a(/) mice, respectively. In addition, P-gp-
mediated alfuzosin efflux was inhibited by GF120918 in mdr1a(/
), wild-type, and Abcg2(/) mice, but not in mdr1a(/) mice,
which confirmed that alfuzosin is a P-gp substrate at the BBB. In
contrast, alfuzosin appears to be transported efficiently by BCRP only
when Bcrp is overexpressed in vitro. Alfuzosin Clup and the brain/
plasma concentration ratio was comparable between wild-type and
Abcg2(/) mice and coperfusion with GF120918 did not increase
alfuzosin Clup in mdr1a(/) mice. Taken together, these data indi-
cate that alfuzosin is not transported by Bcrp at the BBB. In all mouse
strains, alfuzosin did not cross the BBB substantially, and brain
concentrations were much lower than plasma concentrations.
Dipyridamole has been reported to be a substrate of human BCRP
in both human embryonic kidney and MDCK cell lines stably trans-
fected with human BCRP (Zhang et al., 2005b). The current study
confirms that dipyridamole interacts with murine Bcrp and human
P-gp in vitro (Table 1; Fig. 2). Brain uptake of dipyridamole did not
appear to be concentration-dependent in the range of 1 to 5 M that




























































FIG. 6. Initial brain Clup (milliliters per minute per 100 g of brain) of dipyridamole
in the absence (f) and presence () of coperfusion with the P-gp and Bcrp inhibitor
GF120918 in wild-type and Abcg2(/) mice (A) and mdr1a(/) and
mdr1a(/) mice (B). Two-way ANOVA was used to determine the statistical
significance of the GF120918 inhibitory effect and Bcrp effect [wild-type versus
Abcg2(/)] or P-gp effect [mdr1a(/) versus mdr1a(/)]. , statistical dif-























FIG. 7. Brain/plasma concentration ratios for alfuzosin and dipyridamole in wild-
type and Abcg2(/) mice, mdr1a(/), and mdr1a(/) mice after 24 h of
osmotic minipump administration. Data are presented as mean  S.D. (n  3).
Two-tailed Student’s t tests were used to compare brain/plasma concentration ratios
between wild-type and Abcg2(/) mice and between mdr1a(/) and
mdr1a(/) mice. , statistical difference (p  0.05) between mdr1a(/) and
mdr1a(/) mice for alfuzosin brain penetration.
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tration of 3.5 M (1.77 g/ml) in the clinic (Hervey and Goa, 1999).
In addition, brain penetration did not vary between wild-type versus
Abcg2(/) mice. Coperfusion with GF120918 did not increase brain
uptake in mdr1a(/) mice, animals that express Bcrp, but not P-gp,
at the BBB. Thus, Bcrp cannot be an important factor in determining
dipyridamole brain uptake. In addition, the initial rate of dipyridamole
brain uptake did not differ between mdr1a(/) and mdr1a(/)
mice, also suggesting that dipyridamole is not transported by P-gp at
the mouse BBB.
Efflux of [14C]LY2228820 was mediated by Bcrp in vitro.
[14C]LY2228820 transport across the BBB was highly permeable,
consistent with the rapid passive diffusion observed in in vitro cell
monolayers. Brain uptake of [14C]LY2228820 was almost perfusion
flow rate-limited in mdr1a(/) mice. In mdr1a(/) mice,
[14C]LY2228820 brain uptake decreased 60%. [14C]LY2228820
brain uptake in Abcg2(/) mice was comparable to that in wild-type
and Abcg2(/) mice, indicating that [14C]LY2228820 brain uptake
is not limited by Bcrp.
Taken together, all four model compounds appeared to interact with
Bcrp in the MDCK-Bcrp cell line in vitro. However, none was
transported by Bcrp at the mouse BBB, using the genetic knockout
models, i.e., Bcrp-competent (wild type) and Bcrp-deficient
[Abcg2(/)], as well as P-gp-competent [mdr1a(/)] and P-gp-
deficient [mdr1a(/)] mouse models for comparison or chemical
inhibition with GF120918, an inhibitor of P-gp and Bcrp. It is widely
accepted that genetic knockout models are equivalent and essentially
interchangeable with specific chemical knockout models, especially
for cases in which the desired genetic knockout models are not
available, as is most common in rat studies. However, the compen-
satory regulation of other transporter proteins after knockout of a
specific gene and the specificity of inhibitors are always fundamental
concerns in functional studies. Bcrp mRNA has been reported to be
up-regulated in mdr1a(/) FVB mice and was 3-fold higher than
that in mdr1a(/) FVB mice (Cisternino et al., 2004). Other evi-
dence suggested that mRNA levels of mdr1a, Mrp1, Mrp4, and oatp2
were not changed in Bcrp knockout mice (Lee et al., 2005). Likewise,
chemical inhibitors such as PSC833 for P-gp, probenecid for Mrps,
and GF120918 for both P-gp and Bcrp are widely used in the litera-
ture. Cyclosporin A, which has been regarded as a specific P-gp
inhibitor, has recently been demonstrated to inhibit Bcrp and OATPs
(Xia et al., 2007). In a quercetin in situ rat brain perfusion study,
coperfusion with the P-gp inhibitor PSC833 did not change Clup of
quercetin, whereas coperfusion with the P-gp/Bcrp inhibitor
GF120918 significantly enhanced brain uptake of quercetin (Youdim
et al., 2004). The authors concluded that Bcrp was involved in
quercetin brain uptake. In the absence of appropriate comparisons
with a genetic knockout model or information regarding the specific-
ity of a given inhibitor for a transporter, such a conclusion is poten-
tially erroneous.
Western blot analysis demonstrated that Bcrp was expressed at the
BBB of the wild-type mice (Fig. 3), and this finding was consistent
with previous studies on the expression of Bcrp at the BBB (Cis-
ternino et al., 2004; Lee et al., 2005). However, a recent observation
demonstrated that protein expression of Bcrp in human and rat brain
microvessel endothelial cells is much lower than that in the in vitro
overexpressed system (Lee et al., 2007). This difference in protein
expression might explain the discrepancies between the in vitro cell
line model and in situ or in vivo animal models. However, as an
overexpressed cell line model, good in vitro-in vivo correlation has
been identified for the P-gp efflux ratio in the brain (Adachi et al.,
2001), in which P-gp is abundantly expressed.
In summary, the results of the present study suggest that Bcrp plays
a minor role in brain distribution of cimetidine, alfuzosin, dipyridam-
ole, and LY2228820, although each of these compounds interacted
with Bcrp in transfected cell line models. Together with previously
published data on prazosin, dehydroepiandrosterone sulfate, and mi-
toxantrone (Cisternino et al., 2004; Lee et al., 2005), these results
suggest that Bcrp does not contribute significantly to murine BBB
function in most cases or from a drug screening and development
standpoint. Yet, exceptions do occur as demonstrated by a recent
study showing that Bcrp is rate-limiting for several phytoestrogens at
murine BBB (Enokizono et al., 2007). Another speculation regarding
the role of Bcrp at the BBB is that Bcrp and P-gp work together to
limit the brain penetration of therapeutic agents (de Vries et al., 2007)
clogD7.4



























































































FIG. 8. Relationship between the initial uptake clear-
ance of substrates in mdr1a(/) mice [Clup(/)]
and calculated octanol-water partition coefficient at pH
7.4 (clogD7.4) (A) and the in vitro Papp in A-B (F) or in
B-A (Œ) direction (B), the in vitro Pcell in A-B (F)
direction (C), and the percent dose of cellular accumu-
lation [log(%Ccell)] in MDCKII-Bcrp cells incubated
with 20 M chrysin (D).
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or CNS toxic effects (Erdilyi et al., 2008). The present results also
raise the related question of the specific role of organic anion trans-
porters in the overall barrier function at the blood-brain interface. It
has been shown that inhibition of Mrp2 and Mrp4 significantly
enhanced brain exposure of antiepileptic drugs, topotecan, and nucle-
otides; however, the efflux effects observed were modest and all less
than 2-fold (Potschka et al., 2003; Leggas et al., 2004; Belinsky et al.,
2007). Our studies with phenytoin, valproic acid, and ritonavir using
Mrp2-competent and Mrp2-deficient CF57BL/6 mice and in situ brain
perfusion demonstrated no significant Mrp2 function at the BBB (R.
Zhao and G. M. Pollack, unpublished data). The spectrum of reports
to date suggest that P-gp, but not other ABC efflux transporters,
provides the primary transport-mediated attenuation of brain uptake in
the intact BBB. Caution must be taken in the design and interpretation
of in vitro and in situ experiments before assigning specific functional
importance to a given efflux transport system in the in vivo situation.
In this regard, the current results with alfuzosin may serve as a useful
template. These experiments demonstrated that alfuzosin is a P-gp
substrate, with a 4-fold P-gp effect at the BBB. This P-gp effect was
observed consistently among in vitro, in situ, and in vivo experiments.
This type of information set should be available for a given substrate/
transport protein pair before ascribing functional in vivo and potential
pharmacologic/toxicologic importance to that transport protein in
vivo.
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